Centre De Cancerologue Du Grand Montpellier

At Centre De Cancerologue Du Grand Montpellier, much of the clinical trial activity focuses on Neoplasms, especially breast cancer, lung cancer, colorectal cancer, and other advanced solid tumors. These studies are designed to test new cancer therapies, compare treatment options, and improve outcomes for patients with difficult-to-treat or recurrent disease.

• Advanced and metastatic breast cancer, including HER2-positive, HER2-low, and hormone receptor-positive disease
• Non-small cell lung cancer, including EGFR- and KRAS-driven disease
• Colorectal cancer and other solid tumors with unmet treatment needs

Researchers at this medical oncology site are evaluating whether newer targeted and immunotherapy-based approaches can better control cancer growth and delay progression.

The site has a strong portfolio in breast cancer research, covering early-stage, locally advanced, metastatic, and treatment-resistant disease. Trials are exploring ways to improve recurrence prevention, refine endocrine therapy, and assess newer targeted treatments for patients with HER2-positive, HER2-negative, and triple-negative breast cancer.

• Hormone receptor-positive and HER2-negative breast cancer
• HER2-positive and HER2-low breast cancer
• Triple-negative breast cancer and residual disease after surgery

These studies aim to identify more effective treatment strategies, including therapies intended to reduce recurrence risk and improve disease control in both early and advanced settings.

Clinical trials at this Montpellier site also address respiratory tract diseases, with a particular emphasis on non-small cell lung cancer and small cell lung cancer. The research includes patients with advanced disease and tumor subtypes defined by markers such as EGFR, PD-L1, and KRAS.

• Locally advanced and metastatic non-small cell lung cancer
• Limited-stage small cell lung cancer
• Molecularly defined lung cancers, including EGFR exon 20 insertion and KRAS G12C mutations

The main purpose is to evaluate new treatment combinations and targeted approaches that may improve survival and disease control beyond standard care.

Another major area of research involves male urogenital diseases, especially prostate cancer, bladder cancer, and urothelial carcinoma. The trials explore both earlier and advanced disease, including settings where patients need better options after standard treatment.

• High-risk and recurrent prostate cancer
• Muscle-invasive and non-muscle-invasive bladder cancer
• Locally advanced or metastatic urothelial carcinoma

These studies are focused on testing new therapies, strengthening post-surgery treatment strategies, and improving long-term control of cancer in the urinary tract.

The site’s digestive system disease portfolio includes colon cancer and colorectal cancer, with trials spanning adjuvant and metastatic settings. Research is also being done in biomarker-informed treatment selection, reflecting a growing interest in more personalized cancer care.

• Stage II and stage III colon cancer
• Metastatic colorectal cancer
• KRAS-mutated colorectal adenocarcinoma

These trials are intended to improve treatment effectiveness, guide therapy choices more precisely, and reduce the risk of recurrence or progression.

A large share of the research at Centre De Cancerologue Du Grand Montpellier centers on immunotherapy and targeted therapy across multiple cancer types. The studies examine whether combining modern immune-based treatments with targeted agents can improve response rates and extend progression-free survival.

• Immune checkpoint inhibitor-based combinations
• Targeted treatments for biomarker-defined cancers
• New approaches for patients whose disease has returned or spread

Overall, this work aims to broaden treatment options and support more effective, individualized cancer care for patients across several tumor types.